Literature DB >> 10195627

Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors.

L A Hodgson1, G V Ludwig, J F Smith.   

Abstract

Recombinant baculoviruses expressing the structural proteins of Venezuelan equine encephalitis virus (VEE) have been constructed and the intracellular processing, antigenicity, and immunogenicity of the expression products have been assessed. Baculoviruses expressing the entire structural protein region (C-E3-E2-6K-E1), or the complete glycoprotein region (E3-E2-6K-E1), generated products in Sf9 cells that were accurately and completely processed, and resulted in mature proteins that were antigenically and electrophoretically indistinguishable from authentic viral proteins. These products were highly immunogenic in BALB/c mice, induced efficient VEE neutralizing responses, and protected these animals against challenge with virulent VEE. Expression of individual glycoprotein regions (E3-E2 and 6K-E1) generated products that were accurately but incompletely processed, and induced non-neutralizing antibodies that reacted more efficiently with denatured than native VEE proteins. Nonetheless, immunization with the 6K-E1 expression product provided complete protection against VEE challenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195627     DOI: 10.1016/s0264-410x(98)00335-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses.

Authors:  Amber B Rico; Aaron T Phillips; Tony Schountz; Donald L Jarvis; Ronald B Tjalkens; Ann M Powers; Ken E Olson
Journal:  Virology       Date:  2016-09-12       Impact factor: 3.616

2.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  Factors affecting recombinant Western equine encephalitis virus glycoprotein production in the baculovirus system.

Authors:  Ann M Toth; Christoph Geisler; Jared J Aumiller; Donald L Jarvis
Journal:  Protein Expr Purif       Date:  2011-08-16       Impact factor: 1.650

4.  Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.

Authors:  Marcelo M Samsa; Lesley C Dupuy; Clayton W Beard; Carolyn M Six; Connie S Schmaljohn; Peter W Mason; Andrew J Geall; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-01-07       Impact factor: 11.454

5.  A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Authors:  Lesley C Dupuy; Michelle J Richards; Barry Ellefsen; Lillian Chau; Alain Luxembourg; Drew Hannaman; Brian D Livingston; Connie S Schmaljohn
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

Review 6.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

7.  Identification of Western equine encephalitis virus structural proteins that confer protection after DNA vaccination.

Authors:  Penelope J Gauci; Josh Q H Wu; George A Rayner; Nicole D Barabé; Leslie P Nagata; David F Proll
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

8.  Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine.

Authors:  Irina Tretyakova; Igor S Lukashevich; Pamela Glass; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  Vaccine       Date:  2012-12-31       Impact factor: 3.641

9.  Low temperature-dependent salmonid alphavirus glycoprotein processing and recombinant virus-like particle formation.

Authors:  Stefan W Metz; Femke Feenstra; Stephane Villoing; Marielle C van Hulten; Jan W van Lent; Joseph Koumans; Just M Vlak; Gorben P Pijlman
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

10.  Effective chikungunya virus-like particle vaccine produced in insect cells.

Authors:  Stefan W Metz; Joy Gardner; Corinne Geertsema; Thuy T Le; Lucas Goh; Just M Vlak; Andreas Suhrbier; Gorben P Pijlman
Journal:  PLoS Negl Trop Dis       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.